Haemonetics Co. (NYSE:HAE) Receives $106.14 Average PT from Analysts

Haemonetics Co. (NYSE:HAE) has received an average recommendation of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $106.14.

A number of research analysts have commented on HAE shares. BTIG Research started coverage on shares of Haemonetics in a research report on Tuesday, September 10th. They set a “buy” rating and a $112.00 target price on the stock. Barrington Research reissued an “outperform” rating and set a $108.00 target price on shares of Haemonetics in a research report on Monday, September 23rd. JMP Securities reiterated a “market outperform” rating and set a $125.00 price objective on shares of Haemonetics in a research note on Tuesday, August 13th. Bank of America initiated coverage on shares of Haemonetics in a research note on Wednesday, September 11th. They set a “neutral” rating and a $85.00 price objective for the company. Finally, Citigroup reduced their price objective on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, August 22nd.

Haemonetics Trading Up 0.4 %

HAE stock opened at $71.48 on Friday. The company has a market capitalization of $3.66 billion, a PE ratio of 32.05, a P/E/G ratio of 1.11 and a beta of 0.32. Haemonetics has a 12 month low of $70.25 and a 12 month high of $97.97. The firm’s 50-day moving average is $75.46 and its 200 day moving average is $82.74. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.76 and a quick ratio of 2.33.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing the consensus estimate of $1.03 by ($0.01). The company had revenue of $336.17 million during the quarter, compared to analysts’ expectations of $335.08 million. Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The company’s quarterly revenue was up 8.0% on a year-over-year basis. During the same period in the prior year, the business earned $1.05 EPS. On average, research analysts anticipate that Haemonetics will post 4.57 EPS for the current year.

Institutional Trading of Haemonetics

Several large investors have recently bought and sold shares of HAE. Allspring Global Investments Holdings LLC grew its position in Haemonetics by 132.8% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 502,993 shares of the medical instruments supplier’s stock worth $42,930,000 after purchasing an additional 286,897 shares during the last quarter. State of Michigan Retirement System grew its position in Haemonetics by 2.5% during the 1st quarter. State of Michigan Retirement System now owns 12,474 shares of the medical instruments supplier’s stock worth $1,065,000 after purchasing an additional 300 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Haemonetics by 1.9% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 23,302 shares of the medical instruments supplier’s stock valued at $1,844,000 after acquiring an additional 428 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Haemonetics by 6.9% in the 1st quarter. BNP Paribas Financial Markets now owns 28,971 shares of the medical instruments supplier’s stock valued at $2,473,000 after acquiring an additional 1,874 shares during the last quarter. Finally, Central Pacific Bank Trust Division purchased a new stake in shares of Haemonetics in the 1st quarter valued at $139,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.